2018

Q1

– Fast Track Designation for RM-1929 in Recurrent HNSCC.

 

Q3

– Completion of Japan Phase 1 study for RM-1929 in Recurrent HNSCC.

 

Q4

– Initiate Global Phase 3 studies for ASP-1929 in Recurrent HNSCC.

– $284M Series C financing